title: Renal vein immunoreactive renin in patients with renal artery stenosis and essential hypertension.
abstract: In 36 patients with unilateral renal artery stenosis and in 24 with essential hypertension the plasma levels of total immunoreactive renin, and enzymatically active renin were measured in both renal veins (V) and in the aorta (A) by direct RIA by using monoclonal renin antibodies. Active renin and trypsin-activatable inactive renin were also measured by indirect RIA with angiotensin-I antibodies. The V/A ratio for the different forms of renin calculated from the results of direct and indirect RIA were not different. The V/A ratio of active renin for the kidney with the stenotic artery was 3.04 +/- 0.28 (mean +/- sem) with direct and 3.02 +/- 0.25 with indirect RIA. The contralateral ratio was 1.04 +/- 0.02 with the direct and 1.05 +/- 0.02 with the indirect RIA. In essential hypertension it was 1.28 +/- 0.04 with direct RIA and 1.28 +/- 0.04 with indirect RIA. Chronic treatment with captopril had no influence on this ratio in both patients groups. The V/A ratio of total immunoreactive renin was lower than that of active renin and this ratio had lost discriminative power for lateralization. This ratio was significantly greater than one on the affected side in renal artery stenosis but not contralaterally and in essential hypertension. This study shows that renin activity after trypsin-activation of plasma is an accurate measure of the total renin concentration, i.e. active renin plus prorenin. It also shows that a kidney with a stenotic artery secretes inactive renin, which is immunologically related to active renin and is likely to be prorenin. Direct RIA for measuring active renin is technically more simple than indirect RIA. Direct RIA however is somewhat less sensitive. For measuring the V/A ratio for active renin in patients with renal artery stenosis this can be overcome by stimulating the renin-angiotensin system for instance by captopril.
authors.affiliation: Department of Internal Medicine I, University Hospital Dykzigt, Rotterdam, The Netherlands.
authors.forename: F H
authors.initials: FH
authors.lastname: Derkx
authors.forename: H L
authors.initials: HL
authors.lastname: Tan-Tjiong
authors.forename: A J
authors.initials: AJ
authors.lastname: van Seyen
authors.forename: G J
authors.initials: GJ
authors.lastname: Wenting
authors.forename: A J
authors.initials: AJ
authors.lastname: Man in 't Veld
authors.forename: M A
authors.initials: MA
authors.lastname: Schalekamp
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D001012:Aorta, Abdominal / Q000032:analysis; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D006978:Hypertension, Renovascular / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D011863:Radioimmunoassay; D012078:Renal Artery Obstruction / Q000097:blood* / Q000150:complications; D012082:Renal Veins / Q000032:analysis*; D012083:Renin / Q000097:blood* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D002216:Captopril; D012083:Renin